Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19

NCT04528667 is registered in ClinicalTrials.gov with Sorrento Therapeutics, Inc. as lead sponsor.

NCT NCT04528667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04528667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19
Lead sponsor
Sorrento Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 6, 2021
Completion date
October 7, 2021
Enrollment
396 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19